-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $85

Benzinga·03/11/2026 10:59:02
Listen to the news
B of A Securities analyst Geoff Meacham maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $97 to $85.